Why the study?
Do low-molecular-weight heparins improve VTE outcomes and survival in patients with cancer compared to vitamin K antagonists?
Population
Patients with cancer at risk of developing venous thromboembolism (VTE) or with VTE
Comparison
Low-molecular-weight heparins (LMWHs) vs Vitamin K antagonists
Design
Review
Authors
Loading...
Supports LMWH preference for cancer VTE; leaves survival benefit open, warranting targeted trials.
Do low-molecular-weight heparins improve VTE outcomes and survival in patients with cancer compared to vitamin K antagonists?
LMWHs are preferred over vitamin K antagonists for VTE management in cancer patients, but their potential to directly improve cancer survival requires further clarification.
Anna Falanga (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: